1. Pink Sheet
  2. >>Agency Leadership

Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs

 
• By Jessica Merrill

Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”

Valeant Pharmaceuticals International Inc. is turning its back on CEO J. Michael Pearson, the man who built Valeant into a Wall Street darling through a strategy of acquisitions, cost cuts and price hikes. Now that elements of that strategy have backfired and the company’s stock price has fizzled like a sparkler in a downpour, the company announced March 21 that Pearson will be replaced by a successor yet to be named.

Valeant has begun the search for a new chief executive, who will be charged with turning around the troubled company,...

More from Agency Leadership

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.